Innovative Technology Focus Hydra Biosciences specializes in novel ion channel research, particularly TRP pathways, making it a key partner for pharmaceutical companies seeking groundbreaking pain and inflammation therapies.
Strategic Acquisition Activity Recent asset sales to Eli Lilly and active collaborations position Hydra as a valuable collaborator or acquisition target for large biopharma firms looking to expand into ion channel drug development.
Clinical Pipeline Development With recent Series D funding earmarked for clinical trials, Hydra demonstrates growth potential and opportunities for suppliers and service providers supporting clinical-stage research.
Niche Market Expertise Specialization in unmet medical needs like chronic pain and pulmonary diseases presents opportunities for partners with innovative delivery systems or complementary therapeutics.
Investing in Growth Despite a small team, Hydra's significant funding and strategic focus suggest potential expansion, making it an appealing collaborator for technology providers, research tools, and funding partners.
$10B
$10B
$1B$10B
$10B
$1B$10B
$10B
$1B$10B
$10B
$10B
$10BHydra Biosciences uses 8 technology products and services including Google AdSense, AT Internet XiTi, Module Federation, and more. Explore Hydra Biosciences's tech stack below.
| Hydra Biosciences Email Formats | Percentage |
| FLast@hydrabiosciences.com | 54% |
| First.Last@hydrabiosciences.com | 23% |
| Last@hydrabiosciences.com | 14% |
| LastFir@hydrabiosciences.com | 9% |
Biotechnology ResearchMassachusetts, United States2-10 Employees
Hydra Biosciences is a privately held clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that develops drugs to treat pain, inflammation, renal disease, anxiety and pulmonary disease using its expertise in novel ion channels. Hydra Biosciences’ proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.
Company Overview
Media & News
Funding & FinancialsHydra Biosciences has raised a total of $11M of funding over 6 rounds. Their latest funding round was raised on Mar 31, 2015 in the amount of $11M.
Hydra Biosciences's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsHydra Biosciences has raised a total of $11M of funding over 6 rounds. Their latest funding round was raised on Mar 31, 2015 in the amount of $11M.
Hydra Biosciences's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com